136 related articles for article (PubMed ID: 8940864)
41. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
[TBL] [Abstract][Full Text] [Related]
42. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
Blennow K; Wallin A; Agren H; Spenger C; Siegfried J; Vanmechelen E
Mol Chem Neuropathol; 1995 Dec; 26(3):231-45. PubMed ID: 8748926
[TBL] [Abstract][Full Text] [Related]
43. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
44. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
[TBL] [Abstract][Full Text] [Related]
45. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification.
Yamamori H; Khatoon S; Grundke-Iqbal I; Blennow K; Ewers M; Hampel H; Iqbal K
Neurosci Lett; 2007 May; 418(2):186-9. PubMed ID: 17400380
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
47. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.
Russell CL; Mitra V; Hansson K; Blennow K; Gobom J; Zetterberg H; Hiltunen M; Ward M; Pike I
J Alzheimers Dis; 2017; 55(1):303-313. PubMed ID: 27636850
[TBL] [Abstract][Full Text] [Related]
51. No added diagnostic value of non-phosphorylated tau fraction (p-tau
Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
[TBL] [Abstract][Full Text] [Related]
52. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.
Fania C; Arosio B; Capitanio D; Torretta E; Gussago C; Ferri E; Mari D; Gelfi C
PLoS One; 2017; 12(6):e0179280. PubMed ID: 28628634
[TBL] [Abstract][Full Text] [Related]
53. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
[TBL] [Abstract][Full Text] [Related]
55. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
56. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
Hu YY; He SS; Wang X; Duan QH; Grundke-Iqbal I; Iqbal K; Wang J
Am J Pathol; 2002 Apr; 160(4):1269-78. PubMed ID: 11943712
[TBL] [Abstract][Full Text] [Related]
57. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
58. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.
Lewczuk P; Lelental N; Lachmann I; Holzer M; Flach K; Brandner S; Engelborghs S; Teunissen CE; Zetterberg H; Molinuevo JL; Mroczko B; Blennow K; Popp J; Parnetti L; Chiasserini D; Perret-Liaudet A; Spitzer P; Maler JM; Kornhuber J
J Alzheimers Dis; 2017; 55(1):159-170. PubMed ID: 27662295
[TBL] [Abstract][Full Text] [Related]
59. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?
Kapaki E; Kilidireas K; Paraskevas GP; Michalopoulou M; Patsouris E
J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):401-3. PubMed ID: 11511720
[TBL] [Abstract][Full Text] [Related]
60. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
